Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2025)

Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Pharming Group Nv (NASDAQ:PHAR) is the #1 top biotech stock out of 616 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Pharming Group Nv (NASDAQ:PHAR) is: Value: B, Growth: B, Momentum: A, Sentiment: B, Safety: C, Financials: B, and AI: A.

Pharming Group Nv (NASDAQ:PHAR) has a Due Diligence Score of 26, which is 3 points higher than the biotech industry average of 23.

PHAR passed 8 out of 33 due diligence checks and has average fundamentals. Pharming Group Nv has seen its stock return 73.3% over the past year, overperforming other biotech stocks by 116 percentage points.

Alnylam Pharmaceuticals (NASDAQ:ALNY) is the #2 top biotech stock out of 616 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Alnylam Pharmaceuticals (NASDAQ:ALNY) is: Value: C, Growth: A, Momentum: B, Sentiment: A, Safety: D, Financials: B, and AI: B.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a Due Diligence Score of 45, which is 22 points higher than the biotech industry average of 23.

ALNY passed 16 out of 33 due diligence checks and has strong fundamentals. Alnylam Pharmaceuticals has seen its stock return 68.32% over the past year, overperforming other biotech stocks by 111 percentage points.

Alnylam Pharmaceuticals has an average 1 year price target of $491.28, an upside of 23.67% from Alnylam Pharmaceuticals's current stock price of $397.25.

Alnylam Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 25 analysts covering Alnylam Pharmaceuticals, 48% have issued a Strong Buy rating, 36% have issued a Buy, 16% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #3 top biotech stock out of 616 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: C, Momentum: B, Sentiment: A, Safety: C, Financials: A, and AI: B.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 46, which is 23 points higher than the biotech industry average of 23.

AUPH passed 15 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 72.52% over the past year, overperforming other biotech stocks by 115 percentage points.

Aurinia Pharmaceuticals has an average 1 year price target of $17.25, an upside of 9.04% from Aurinia Pharmaceuticals's current stock price of $15.82.

Aurinia Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Aurinia Pharmaceuticals, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 11.42%, which is 9 percentage points higher than the biotech industry average of 2.8%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 2.26%, which is -1 percentage points lower than the biotech industry average of 2.8%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 49.4% indicates that its dividend yield is sustainable for the long-term.

Bio Techne (NASDAQ:TECH) has an annual dividend yield of 0.54%, which is -2 percentage points lower than the biotech industry average of 2.8%. Bio Techne's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Bio Techne's dividend has not shown consistent growth over the last 10 years.

Bio Techne's dividend payout ratio of 64% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were down -1.44% in the last day, and down -2.03% over the last week.

We couldn't find a catalyst for why biotech stocks are down.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 41 points higher than the biotech industry average of 16. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 10.51% in the past year. It has overperformed other stocks in the biotech industry by 53 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 27 points higher than the biotech industry average of 16. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 92.01% in the past year. It has overperformed other stocks in the biotech industry by 135 percentage points.

Innoviva (NASDAQ:INVA) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Innoviva has a valuation score of 43, which is 27 points higher than the biotech industry average of 16. It passed 3 out of 7 valuation due diligence checks.

Innoviva's stock has gained 14.44% in the past year. It has overperformed other stocks in the biotech industry by 57 percentage points.

61.97% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 53.28% over the next year.

3.5% of biotech stocks have a Zen Rating of A (Strong Buy), 6.38% of biotech stocks are rated B (Buy), 46.71% are rated C (Hold), 32.51% are rated D (Sell), and 10.91% are rated F (Strong Sell).